Drug Type Antisense oligonucleotides |
Synonyms EZN 3042, SPC 3042, SPC-3042 |
Target |
Mechanism BIRC5 gene inhibitors |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Phase 1 | US | 24 Aug 2010 | |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Phase 1 | AU | 24 Aug 2010 | |
Recurrent Adult Acute Lymphoblastic Leukemia | Phase 1 | US | 24 Aug 2010 | |
Recurrent Adult Acute Lymphoblastic Leukemia | Phase 1 | AU | 24 Aug 2010 | |
Acute Lymphoblastic Leukemia | Phase 1 | BR | - | |
Acute Lymphoblastic Leukemia | Phase 1 | CA | - | |
Acute Lymphoblastic Leukemia | Phase 1 | - | - | |
Lymphoma | Phase 1 | US | - | - |
Lymphoma | Phase 1 | FR | - | - |
Lymphoma | Phase 1 | - | - |
Phase 1 | 6 | EZN (EZN Dose Level 1) | btjqxwuxbi(itisylocne) = vuiotufusq zecknwlvrk (rtrdupioej, ockvplclro - gqjriqhpyp) View more | - | 24 Jul 2019 | ||
EZN (EZN Dose Level 0) | fomufkknra(qsgzrsqfcd) = hvxyxtxhcs flotxaeuvv (xutjwnoknc, ekcvdzljei - jltrjvkdbw) View more | ||||||
Phase 1 | 25 | mlffhqonus(hqjgczhrpv) = wqhjmodtlw clfbqbwwen (yyjbypohju ) | - | 15 Apr 2011 | |||
EZN-3042 + D | vygkmgrndo(tgitqcncni) = szbddfrgil azmknpyzqg (hlfzscrfkd ) |